Abstract:Volumetric absorptive microsamplers (VAMS) have been developed recently as a promising tool for clinical blood sampling. Compared to dried blood spot samples analyzed by accurate stable isotope dilution assays (SIDAs), the new technique could provide further substantial miniaturizing of folate assays by eliminating hematocrit effects and uneven analyte distribution within the sample. Herein, we present a miniaturized SIDA coupled with LC-MS/MS measurement of 5-methyltetrahydrofolic acid as main folate vitamer in whole blood (WB) using [13C5]-5-methyltetrahydrofolic acid as internal standard. Elution and extraction of only 10.8 μL-dried WB were carried out by centrifugation followed by enzymatic treatment for polyglutamate deconjugation. Matrix separation was achieved by heating and centrifugation. To verify applicability, WB folate status of 11 volunteers was screened. Limits of detection and limits of quantitation were 9 and 26 nmol·L-1, respectively, which is sufficiently low for screening folate status. Recoveries were 97 (±5.8), 99 (±2.8), and 96 (±6.1)% for 800, 400, and 200 nmol L-1 5-methyltetrahydrofolic acid, respectively. Precision of the LC-MS/MS instrument and inter-assay precision trials revealed CVs of 8.1 and 3.5% (294 nmol L-1), respectively, thus confirming reproducible and precise quantitation. Compared to fresh WB, no significant degradation of 5-methyltetrahydrofolate was observed after 2.5 h of drying at room temperature. VAMS 5-CH3-H4folate was stable for at least 3 weeks at -20°C. In our pilot study, accurate and diagnostically conclusive determination of folate status was verified. Nevertheless, blood sampling should be performed by trained individuals to avoid substantial errors concerning the absorbed volume. Endogenous folate in rat serum and chicken pancreas caused a significant background especially at low blood 5-CH3-H4folate levels and, thus, for polyglutamate deconjugation, these background folates or alternative mixtures need to be removed. The superior feasibility of a minimized blood collection with VAMS allows further progress regarding time- and cost-effective methodologies in newborn or population screenings for 5-methyltetrahydrofolate status. Further steps toward minimization could include an automated assay coupled with UPLC-MS/MS.

Volumetric absorptive microsampling coupled with UHPLC-MS/MS for the determination of Lyso-Gb3 as Fabry disease diagnostic biomarker

Using Liquid Chromatography-Tandem Mass Spectrometry in Detecting Plasma Lyso-GL3 Levels in Patients with Fabry Disease and the Association Analysis of Phenotype-Genotype of the Disease

Clinical Significance of Plasma Globotriaosylsphingosine Levels in Chinese Patients with Fabry Disease

Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

Exploring the Diagnostic Potential of miRNA Signatures in the Fabry Disease Serum: A Comparative Study of Automated and Manual Sample Isolations

Value of α-galactosidase A activity assay in diagnosis and screening of Fabry's disease

Plasma Globotriaosylsphingosine (lysogb3) Could Be a Biomarker for Fabry Disease with a Chinese Hotspot Late-Onset Mutation (IVS4+919G>A).

Myocardial Fibrosis Quantification Methods by Cardiovascular Magnetic Resonance Imaging in Patients with Fabry Disease

Early Detection of the Irreversible Cardiac Damages in the Adults with Late Onset Fabry Disease in a Large Cohort Study Via Newborn Screening

Assessing Volumetric Absorptive Microsampling Coupled with Stable Isotope Dilution Assay and Liquid Chromatography-Tandem Mass Spectrometry as Potential Diagnostic Tool for Whole Blood 5-Methyltetrahydrofolic Acid

Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression

Multiplexed Derivatization Strategy-Based Dummy Molecularly Imprinted Polymers As Sorbents for Magnetic Dispersive Solid Phase Extraction of Globotriaosylsphingosine Prior to UHPLC-MS/MS Quantitation.

The use of high resolution melting analysis to detect Fabry mutations in heterozygous females via dry bloodspots.

Plasma and platelet lipidome changes in Fabry disease

Globotriaosylsphingosine (lyso Gb3) might not be a reliable marker for monitoring the long term therapeutic outcomes of enzyme replacement therapy for late onset Fabry patients …

Detection of α-Galactosidase A Reaction in Samples Extracted from Dried Blood Spots Using Ion-Sensitive Field Effect Transistors

Infrared spectroscopy as a new approach for early fabry disease screening: a pilot study

In vivo demonstration of globotriaosylceramide brain accumulation in Fabry Disease using MR Relaxometry

Quantification of trimethylsilyl derivatives of amino acid disease biomarkers in neonatal blood samples by gas chromatography-mass spectrometry

AB077. Identification of Lysosomal and Extralysosomal Globotriaosylceramide (gb3) Accumulation in Endomyocardial Biopsies Before the Occurrence of Typical Pathological Changes of Fabry Disease

LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease